Global Inflammatory Myopathies Market, Type (Polymyositis, Dermatomyositis, Autoimmune Necrotizing Myopathies, Others), Presence (Acute, Subacute, Chronic), Population Type (Children, Male, Female, Others), Treatment (Medication, Physical Therapy, Heat Therapy, Orthotics, Assistive Devices, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Inflammatory Myopathies Market Analysis and Size
The global inflammatory myopathies market is expected to witness significant growth during the forecast period. As per the records of the Rare Disease Organization, the rate of occurrence of dermatomyositis is projected to be about 9.63 cases per million people worldwide. The estimated event of polymyositis and dermatomyositis (PM/DM) is 5 to 22 per 100,000 persons, with around 1.2 to 19 million persons at risk per year. Cancer-related dermatomyositis is witnessed to occur more frequently in people between the age group of 40 to 50 years. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global inflammatory myopathies market in the forecast period 2022-2029. The expected CAGR of global inflammatory myopathies market is tend to be around 5% in the mentioned forecast period. The market was valued at USD 0.67 billion in 2021, and it would grow upto USD 1 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Inflammatory Myopathies Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Polymyositis, Dermatomyositis, Autoimmune Necrotizing Myopathies, Others), Presence (Acute, Subacute, Chronic), Population Type (Children, Male, Female, Others), Treatment (Medication, Physical Therapy, Heat Therapy, Orthotics, Assistive Devices, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), Endo International Inc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Cipla Inc (India), Dr Reddy's Laboratories Ltd (India), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc (U.S.), Zydus Group (India), Lupin (India), Amorphex Therapeutics Holdings, Inc (U.S.), Bausch Health Companies Inc. (Canada), Accord Healthcare (U.K.), Genentech, Inc (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Inflammatory myopathies is a rare inflammatory disease characterized by weakness and inflammation of muscles and muscle pain. It is the group of three diseases that affects adults and children. Although, polymyositis & dermatomyositis are more common in females than males, and dermatomyositis is more common in children than adults. Symptoms incudes progressive muscle weakness, difficulty swallowing or breathing, tripping or falling, and fatigue after walking or standing.
Global Inflammatory Myopathies Market Dynamics
Drivers
- Increase in Autoimmune Disorders
As per the National Institute of Environmental Health Sciences, more than 80 autoimmune diseases have been identified namely diabetes (type 1), multiple sclerosis, rheumatoid arthritis, lupus, and celiac disease. Increase in the occurrence of these diseases drives the global dermatomyositosis market.
- Rising Demand for Oral Drugs
Oral drugs is projected to boost the market growth. The segment is estimated to enhance the global market as most products are available in capsule and tablet form and it is a very likely route of administration.
Opportunities
- Rise in Elderly Population
According to research, elderly population is more prone to suffer from this disease. According to the Aging World reports from 2015, there were approximately 562 million people 65 and older worldwide, which increased the disease's incidence and fueled the growth of the inflammatory myopathies market.
- Rising Incidence of Dermatomyositis
According to Rare Disease Organization, the rate of incidence of dermatomyositis is estimated to be around 9.63 cases per million people globally. In children, dermatomyositis symptoms commonly occur between 5 and 15 years of age. Around three in 1,000,000 children are affected by juvenile dermatomyositis. In women, chances of dermatomyositis are two times greater than those in men.
- Increasing Demand for Retail Pharmacies
The rise in the number of dermatomyositis therapeutics delivered through retail pharmacies and the increase in the number of retail pharmacies in highly developed countries create opportunities for the market growth. In addition to this, patients choose retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Limited Studies and Surveys
There are very limited studies and surveys that is hampering the growth of the market. Only a minimal amount of data are available with respect to the studies. A few studies mainly focused on groups from a single hospital wherein only a limited number of patients are observed. Thus, this hampers the growth of the market.
- High Cost
The huge expenditure associated with inflammatory myopathies medications hamper the market growth. This disease involves treatment with corticosteroids, different immunosuppressive agents which demands huge expenditure. This acts as a major hindrance for the market.
This global inflammatory myopathies market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global inflammatory myopathies market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Inflammatory Myopathies Market
COVID-19 has left an unparalleled global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period. It has been observed that COVID-19 can induce a systemic inflammatory response, and its clinical appearances are different. Recently, it has been stated that COVID-19 patients may develop myositis and interstitial pulmonary disease similar to inflammatory myopathy.
In the post-pandemic era, the market is expected to rise because of the availability of varied treatment options such as anti-inflammatory therapy may be beneficial to patients. Other than that, physical therapy, heat therapy are also helpful.
Global Inflammatory Myopathies Market Scope
The global inflammatory myopathies market is segmented on the basis of type, population type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Polymyositis
- Dermatomyositis
- Autoimmune Necrotizing Myopathies
- Others
Population Type
- Children
- Male
- Female
- Others
Treatment
- Medication
- Physical Therapy
- Heat Therapy
- Orthotics
- Assistive Devices
- Others
Route of Administration
- Oral
- Topical
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Inflammatory Myopathies Market Regional Analysis/Insights
The global inflammatory myopathies market is analysed and market size insights and trends are provided by type, population type, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global inflammatory myopathies market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for global inflammatory myopathies market throughout the forecasted period due to increased healthcare and R&D expenditure and presence of skilled professionals.
Asia-Pacific dominates the market due to increased inflammatory diseases, increased awareness for joint disorders through advertisement & media and rapidly improving health care infrastructure in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Inflammatory Myopathies Market Share Analysis
The global inflammatory myopathies market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global inflammatory myopathies market
Key players operating in the global inflammatory myopathies market include:
- Novartis AG (Switzerland)
- Endo International Inc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Glenmark Pharmaceuticals Ltd (India)
- Cipla Inc (India)
- Dr Reddy's Laboratories Ltd (India)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc (U.S.)
- Zydus Group (India)
- Lupin (India)
- Amorphex Therapeutics Holdings, Inc (U.S.)
- Bausch Health Companies Inc. (Canada)
- Accord Healthcare (U.K.)
- Genentech, Inc (U.S.)
SKU-